Cat Arthritis Pain Management Biologics

New biologic treatments for feline arthritis represent a major advance in pain management for one of the most common and under-treated conditions in cats.

Key Facts

Osteoarthritis affects an estimated 40-90% of cats over ten years of age
Cats mask pain effectively, meaning arthritis is frequently unrecognised and untreated
Frunevetmab (Solensia) is the first licensed monoclonal antibody for feline OA pain
It targets nerve growth factor, reducing pain signalling with monthly injection
Clinical trials show significant improvement in mobility and owner-assessed welfare measures
NSAIDs for cats carry renal and gastrointestinal risks limiting long-term use
Gabapentin and amantadine are used adjunctively for neuropathic pain components

Welfare Considerations

Feline arthritis is one of the most prevalent sources of chronic pain in companion animals, yet it is frequently unrecognised and undertreated because cats mask pain so effectively. The arrival of licensed feline monoclonal antibody therapy represents a major welfare advance - providing effective, safe long-term pain relief without the side effect risks of NSAIDs. Awareness of this treatment option among cat owners and veterinarians is the key barrier to improved welfare.

What You Can Do

Ask your vet about frunevetmab (Solensia) if your cat is over ten years and showing any mobility changes
Learn to recognise feline arthritis signs including reduced grooming, hesitation to jump and altered facial expression
Schedule annual health checks for senior cats specifically including arthritis assessment
Provide environmental modifications for arthritic cats including ramps, low-sided litter trays and warm beds